PIK3CA and neoplasm: Furthermore, when treating mice with the ICI Nivolumab (αPD-1), we found that the efficacy of Nivolumab in inhibiting tumor growth was markedly lower in the PIK3CA-mutant group compared to the wild-type group (Fig. 2G, H, Fig. S6E, F).